KRAS mutation: from undruggable to druggable in cancer

L Huang, Z Guo, F Wang, L Fu - Signal transduction and targeted …, 2021 - nature.com
Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

The role of wild-type RAS in oncogenic RAS transformation

E Sheffels, RL Kortum - Genes, 2021 - mdpi.com
The RAS family of oncogenes (HRAS, NRAS, and KRAS) are among the most frequently
mutated protein families in cancers. RAS-mutated tumors were originally thought to …

Pancreatic organoids: a frontier method for investigating pancreatic-related diseases

Y Liu, N Li, Y Zhu - International Journal of Molecular Sciences, 2023 - mdpi.com
The pancreas represents an important organ that has not been comprehensively studied in
many fields. To fill this gap, many models have been generated, and traditional models have …

[HTML][HTML] Autophagy inhibition in BRAF-driven cancers

M Foth, M McMahon - Cancers, 2021 - mdpi.com
Simple Summary BRAF is a protein kinase that is frequently mutationally activated in cancer.
Mutant BRAF can be pharmacologically inhibited, which in combination with blockade of its …

Clinicopathological Characteristics and Mutational Landscape of APC, HOXB13, and KRAS among Rwandan Patients with Colorectal Cancer

F Manirakiza, E Rutaganda, H Yamada… - Current Issues in …, 2023 - mdpi.com
Cancer research in Rwanda is estimated to be less than 1% of the total African cancer
research output with limited research on colorectal cancer (CRC). Rwandan patients with …